This article was downloaded by: [University of Michigan] On: 01 April 2013, At: 15:39 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International: The New Journal for **Organic Synthesis**

Publication details, including instructions for authors and subscription information:

http://www.tandfonline.com/loi/uopp20

N-SUBSTITUTED 3-OXA- AND 3-THIA-7-AZABICYCLO[3.3.1]NONANES AS POTENTIAL PRECURSORS OF **ANTIARRHYTHMICS**

Sameer Tyagi^a, Kevin M. Couch^a, Gregory L. Garrison^a, K. Darrell Berlin^a, Benajmin J. Scherlag^b, Eugene Patterson^b & Ralph Lazzara^b

^a Department of Chemistry, Oklahoma State University, Stillwater, OK, 74078, USA

^b VA Medical Center, 923 NE 13th Street, Oklahoma City, OK, 73104, USA

Version of record first published: 11 Feb 2009.

To cite this article: Sameer Tyagi, Kevin M. Couch, Gregory L. Garrison, K. Darrell Berlin, Benajmin J. Scherlag, Eugene Patterson & Ralph Lazzara (1999): N-SUBSTITUTED 3-OXA- AND 3-THIA-7-AZABICYCLO[3.3.1]NONANES AS POTENTIAL PRECURSORS OF ANTIARRHYTHMICS, Organic Preparations and Procedures International: The New Journal for Organic Synthesis, 31:4, 413-421

To link to this article: <u>http://dx.doi.org/10.1080/00304949909355730</u>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings,

demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

N-SUBSTITUTED 3-OXA- AND 3-THIA-7-AZABICYCLO[3.3.1]NONANES AS POTENTIAL PRECURSORS OF ANTIARRHYTHMICS

Sameer Tyagi, Kevin M. Couch, Gregory L. Garrison and K. Darrell Berlin*

Department of Chemistry, Oklahoma State University, Stillwater, OK 74078, USA

Benajmin J. Scherlag, Eugene Patterson and Ralph Lazzara

VA Medical Center, 923 NE 13th Street, Oklahoma City, OK 73104 USA

The need for useful antiarrhythmic agents to treat lethal ventricular tachycardia of the heart remains critical.¹ The skeleton of 3,7-diazabicyclo[3.3.1]nonane constitutes the B and C rings of a variety of lupane alkaloids, *e. g.* sparteine, which is a tetracyclic alkaloid possessing antiarrhythmic



properties.² A small number of examples³ have appeared which demonstrate that the smaller combination of the B and C rings can lead to antiarrhythmic properties, but the area is still in its infancy.⁴ We report herein the preparation and characterization of several unique 3-oxa- and 3-thia-7-azabicyclo[3.3.1]nonanes 11 which have potential as precursors for derivatization to important antiarrhythmics. The structures bear some resemblance to that of tedisamil,⁵ a relatively new Class III antiarrhythmic agent which prevented electrically-induced ventricular fibrillation in rats.⁶ In the general, structure 11, X is O or S while $Y = CH_2$ or SCH_2CH_2S , the latter being a subunit similar to the fivemembered spiro hydrocarbon ring in tedisamil. Antiarrhythmic properties of 11 await evaluation.

The rationale for the synthesis of the 3,7-diheterabicyclo[3.3.1]nonanes is based on the following reasoning. 3,7-Diheterabicyclo[3.3.1]nonanes possess the B and C rings, as in sparteine,

© 1999 by Organic Preparations and Procedures Inc.

and some have exhibited good antiarrhythmic activity in dog models.⁷ Compounds **11a** and **11b** are related to the hydroperchlorate of the precursor amine to **11g** which possesses⁷ Class Ib antiar-rhythmic activity. Amines **11b**, **11c**, and **11f** have structural features reminiscent of those in Tedisamil while **11d** and **11h** are expected to exhibit Class III anatiarrhythmic activity as is known⁸ with certain imidazole-substituted antiarrhythmics. Sulfonamide **11e** was included since some sulfonyl-aminoben-zamides possess⁹ Class III anti-arrhythmic activity. Classifications of antiarrhythmic action by agents are well established.¹⁰

The conversion of $1 \rightarrow 2$ (*Scheme 1*) was a simple double Mannich reaction, but, interestingly, the addition of HCl markedly facilitated the process. Wolff-Kishner reduction of the carbonyl



i) $(H_2CO)_n$, PhCH₂NH₂, HOAc, HCl *ii*) H_2NNH_2 , KOH, TEG, 200° *iii*) HClO₄ *iv*) F₃B•OEt₂, HSCH₂CH₂SH

Scheme 1

group in 2 led to 3 (95%) which was converted to stable salt 11a in good yield (83%). Masking the carbonyl group in 2 occurred *via* the formation of the thioketal 11b (82%), the latter being acidified to salt 11c.

Debenzylation of 3 with *fresh* 10% Pd-C gave the important intermediate 4 which was acylated to give 5 (*Scheme 2*). Although 4 is a light oil and slightly air-sensitive, its potential as a



i) 10% Pd-C/H₃COH/HCO₂NH₄ ii)4-FC₆H₄C(O)Cl/NaOH/H₂CCl₂ iii) Imidazole/ Δ /K₂CO₃/DMSO iv) HClO₄ v) 4-O₂NC₆H₄SO₂Cl/NaOH/H₂CCl₂ vi) TiCl₃/HOAc

Scheme 2

useful synthon for a variety of N-substituted derivatives is significant. Nucleophilic addition/elimination in the reaction of 5 with imidazole required extremely dry conditions and finely powdered K_2CO_3 . The intermediate oil was isolated (38%) and was best converted immediately to stable salt **11d**. *N*-Sulfonation of intermediate **4**, followed by reduction of the nitro group with TiCl₃ in the product **6**, gave **11e**.

Masking the sulfur-containing ketone 7 with ethane-1,2-dithiol (Scheme 3) gave the expected intermediate (84%) which was acidified to give salt **11f** in a fashion similar to that of converting **2** to **11b** to **11c**. Surprisingly, ketone **7** (Scheme 3) was susceptible to debenzylation following N-acylation as shown. To the best of our knowledge, only the electrophilic proton has been successful in attacking a nitrogen atom in a chair-chair 3,7-di-heterabicyclo[3.3.1]nonane system. Indeed, a sparteine derivative, with a boat-chair conformation as a subunit, could only be successfully



i) $F_3B-OEt_2,HSCH_2CH_2SH$ ii) $HClO_4$ iii) $ClCO_2CH_2CCl_3,C_6H_6/cold; \Delta/2 d$ iv) $H_2NNH_2,KOH/TEG,200$ v) HCl vi) $4-FC_6H_4C(O)Cl/NaOH,H_2CCl_2$ vii) Imidazole, $\Delta/K_2CO_3,DMSO$ viii) $HClO_4$

Scheme 3

N-methylated with methyl iodide at 11kbars of pressure at 50° for 170 hours.¹¹ This successful *N*-debenzylation of 7 with $ClCO_2CH_2Cl_3$ is the first in this family of heterocycles as is the isolation of the intermediate 8. Intermediate 8 was characterized and then converted to 9. Acylation of the light oil 9 gave 10 which reacted with imidazole in the usual manner to give an intermediate that was converted to hydroperchlorate 11h. Debenzylation of 7 gave known 12⁷ which was treated with hydrogen chloride gas to give 11g. In summary, syntheses are reported for several 3,7-diheterabicyclo[3.3.1]nonanes with potential antiarrhythmic activity.

EXPERIMENTAL SECTION

Proton and carbon-13 NMR spectra were recorded on a Varian Gemini 300 MHz unit operating at 300.082 and 75.463 MHz, respectively, or on a Varian Inova 400 MHz spectrometer operating at 399.925 and 100.570 MHz, respectively. Chemical shifts are reported in δ values downfield from TMS. IR spectra were taken on a Perkin-Elmer 2000 FTIR unit either as KBr pellets or as films. Melting points were measured on a Thomas-Hoover apparatus and were uncorrected. All solvents were dried prior to use. Intermediate 12 was prepared as reported.⁷ High resolution mass spectral data were collected on a VG analytical instrument, model ZAB-2SE, for all salts with a FAB ionization chamber. Some data on liquids were collected on this unit by the LSIMS/FAB mode using 3-

nitrobenzyl alcohol as the matrix. GC/MS data were gathered on Hewlett-Packard GC1800A (GCD-800 series) with an electron impact (EI) ionization chamber. Elemental analyses were performed by Galbraith Laboratories, Knoxville, TN 37921, or by Atlantic Microlab, Inc., Norcross, GA 30091. All reactions were performed under nitrogen unless otherwise specified. Although no difficulties were encountered with the hydroperchlorates cited herein, due caution and the use of hoods should be exercised.

Preparation of 2.- A mixture of benzylamine (3.21 g, 29.9 mmol), HCl (37%, 1.48 g, 14.9 mmol), glacial acetic acid (2.7 g, 44.9 mmol), and paraformaldehyde (7.2 g, 239.6 mmol) in deoxygenated H₃COH was stirred at reflux (0.25 h). A solution of **1** (3.0 g, 29.9 mmol) in glacial acetic acid (2.7 g, 44.9 mmol) and methanol (25 mL) was added dropwise (0.5 h), and the solution was then boiled (12 h). Cooling the reaction mixture to RT and evaporation of the solvents produced an orange oil which was redissolved in water (75 mL). Ether extracts of the aqueous mixture were discarded, and the remaining mixture was chilled (5°) and made basic (pH ~ 12, NaOH pellets). Extracts (ether, 3 x 50 mL) of the solution were dried (Na₂SO₄), filtered, and concentrated to a viscous, reddish oil. Vacuum distillation (130-140°/0.01 mm) of the oil gave **2** (3.55 g, 51%) as a clear oil which solidified with chilling (- 10°), mp. 37-38°. IR (KBr): 1735 (C=O) cm⁻¹; ¹H NMR (DCCl₃): δ 2.53 (bs, 2 H), 2.93 (dd, 2 H), 3.12 (dd, 2 H), 3.56 (s, 2 H), 3.89 (dd, 2 H), 4.09 (d, 2 H), 7.33 (m, 5 H, Ar-H); ¹³C NMR (DCCl₃) δ 49.4, 57.5, 61.1, 73.4, 127.0, 128.1, 128.4, 137.8 (Ar-C), 211.8 (C=O). GC-MS (EI): Calcd for C₁₄H₁₇NO₂: 231. Found: 231. Ketone **2** was converted directly to **3**.

Preparation of 3.- To a solution of **2** (3.55 g, 15.3 mmol) in triethylene glycol (20 mL) was added KOH pellets (85%, 10.0 g, 153.6 mmol) and hydrazine (95%, 2.58 g, 76.8 mmol). The stirred mixture was boiled (4 h) and then cooled (RT, 1 h). Chilled water (20 mL) was added, and resulting mixture was extracted (ether, 3 x 30 mL). The combined extracts were washed (10% NaOH and saturated brine) and dried (Na₂SO₄). Filtration and concentration of the solution gave a light yellow oil of **3** (3.16 g, 95%). IR (Film): 3030 (Ar-H), 2918, 2819 (alkyl-H) cm⁻¹; ¹H NMR (DCCl₃): δ 1.54 (m, 1 H), 1.70 (bs, 2 H), 1.77 (m, 1 H), 2.31 (dd, 2 H), 2.94 (d, 2 H), 3.50 (s, 2 H), 3.77 (m, 2 H), 3.90 (d, 2 H), 7.36 (m 5 H, Ar-H); ¹³C NMR (DCCl₃): δ 30.30, 30.35, 57.7, 61.7, 63.3, 126.5, 127.9, 128.7, 138.5 (Ar-C). GC-MS (EI): Calcd for C₁₄H₁₉NO: 217. Found: 217. Amine **3** appeared air sensitive and was converted to salt **11a**.

Preparation of 4.- Onto a fresh sample of Pd-C (10%, 0.436 g, ~ 30 mg of catalyst/mmol of **3**) in a system, which had been thoroughly flushed (0.5 h) with and was under nitrogen, was slowly poured deoxygenated H₃COH (30 mL). To this stirred suspension was quickly added amine **3** (3.16 g, 14.58 mmol) and anhydrous ammonium formate (3.67 g, 58.24 mmol). After boiling (1 h), the mixture was cooled to RT and then filtered (celite pad). Concentration of the filtrate gave a light oil which was dissolved in water (30 mL), and the new solution was made basic (pH ~12, 10% aqueous NaOH). Combined extracts (HCCl₃, 4 x 30 mL) of the aqueous solution were dried (Na₂SO₄), filtered, and concentrated to a very faint yellow oil of **4** (1.38 g, 75%). IR (Film): 3431 (N-H), 2933 (alkyl-H) cm⁻¹; ¹H NMR (DCCl₃): δ 1.48 (bs, 2 H), 1.94 (m, 2 H), 2.88 (bs, 1 H), 3.05 (dd, 2 H), 3.16 (d, 2 H), 3.87

(dd, 2 H), 4.03 (d, 2 H); ¹³C NMR (DCCl₃): δ 29.7, 31.6, 51.3, 72.8. MS (LSIMS): Calcd for C₂H₁₂NO: 127. Found: 128 (M⁺ + 1). The sample of **4** was used immediately to prepare derivatives.

Preparation of 5.- To a mixture of **4** (0.30 g, 2.36 mmol) in H₂CCl₂ (7 mL) and aqueous NaOH (10%, 2.36 g, 5.90 mmol) was added dropwise a solution of 4-fluorobenzoyl chloride (0.56 g, 3.54 mmol) in H₂CCl₂ (8 mL) over a period of 5 min. After stirring (6 h), the mixture was extracted (H₂CCl₂, 3 x 10 mL), and the extracts were combined, dried (Na₂SO₄), filtered, and concentrated to a white solid. Recrystallization (EtOAc:hexane, 2:1) gave **5** (0.456 g, 77%), mp. 115-115.5°. IR (KBr): 3069 (Ar-H) 1618 (NC=O) cm⁻¹; ¹H NMR (DCCl₃): δ 1.52 (bs, 2 H), 1.90 (m, 4 H), 3.03 (d, 1 H), 3.26 (d, 1 H), 3.75 (m, 2 H), 4.07 (d, 1 H), 4.86 (d, 1 H), 7.25 (m, 2 H), 8.14 (d, 2 H); ¹³C NMR (DCCl₃): δ 29.7, 29.9, 31.7, 46.8, 52.3, 71.9, 72.2, 115.6, 115.8, 116.4, 116.6, 129.0, 133.4 (Ar-C), 170.2 (NC=O). MS (LSIMS): Calcd for C₁₄H₁₆FNO₂: 249. Found: 250 (M⁺ + 1).

Anal. Calcd for C₁₄H₁₆FNO₂: C, 67.46; H, 6.42; N, 5.62. Found: C, 67.31; H, 6.45; N, 5.67.

Preparation of 8.- To a solution of ketone 7⁷ (6.0 g, 24.2 mmol) in anhydrous benzene (80 mL) chilled to 5° was added dropwise (0.5 h) a solution of 2,2,2-trichloroethyl chloroformate (15.42 g, 72.78 mmol) in anhydrous benzene (15 mL). After stirring (2 h), the mixture was boiled (2 d), after which it was cooled (RT). Evaporation gave an oil which was mixed with 10% NaOH (~80 mL), and the resulting mixture was extracted (H₂CCl₂, 4 x 50 mL). Combined extracts were dried (Na₂SO₄) and concentrated to an oil which was chromatographed (neutral alumina). A mixture of EtOAc:hexane (1:20) removed contaminants, but a more polar mixture of EtOAc:hexane (3:7) allowed isolation of **8** (4.45 g, 53%), mp. 112-113°. IR (KBr): 1720 (C=O), 1707 [NC(O)O] cm⁻¹; ¹H NMR (DCCl₃): δ 2.73 (bd, 2 H), 3.99 (bd, 2 H), 3.40-3.56 (m, 4 H), 4.70-4.88 (m, 4 H); ¹³C NMR (DCCl₃): δ 36.4, 36.5, 46.6, 47.0, 49.7, 49.9, 75.6, 153.5 (NC=O), 211.4. GC-MS (EI): Calcd for C₁₀H₁₂Cl₃NO₃S: 332. Found: 332. *Anal.* Calcd for C₁₀H₁₂Cl₃NO₃S: C, 36.11; H, 3.64; N, 4.21. Found: C, 36.10; H, 3.60; N, 4.18

Preparation of 9.- A mixture of carbamate **8** (4.45 g, 13.01 mmol) in triethylene glycol (60 mL), KOH pellets (85%, 8.04 g, 117.59 mmol), and hydrazine (95%, 4.39 g, 130.06 mmol) was heated (~200°) for 6 h. The reaction mixture was cooled to RT and diluted (chilled water, 80 mL). Combined extracts (ether, 4 x 80 mL) were washed (10% aqueous NaOH and brine), dried (Na₂SO₄), filtered, and concentrated to the oil **9** (1.57 g, 84%). IR (Film): 3200 (N-H) cm⁻¹; ¹H NMR (DCCl₃): δ 1.81-188 (m, 3 H), 1.99 (d, 1 H), 2.67 (d, 2 H), 3.18 (d, 2 H), 3.26 (d, 2 H), 3.35 (d, 2 H), 3.75 (s, 1 H); ¹³C NMR (DCCl₃): δ 26.2, 31.6, 32.6, 51.1.

GC-MS (EI): Calcd for C₇H₁₃NS: 143. Found: 143. Amine 9 was used immediately.

Preparation of 10.- To a solution of 9 (1.14 g, 7.99 mmol) in a biphasic solution of H_2CCl_2 (35 mL) and aqueous NaOH (10%, 7.97 g, 19.87 mmol) was added dropwise a solution of 4-fluorobenzoyl chloride (1.39 g, 8.78 mmol) in H_2CCl_2 (15 mL) over 0.5 h. After stirring overnight (RT), the mixture was diluted with water (50 mL), the layers were separated, and the aqueous layer was extracted (H_2CCl_2 , 4 x 30 mL). Combined extracts were dried (Na_2SO_4), filtered, and concentrated to an oil which was chromatographed (neutral alumina, ethyl acetate:hexane, 2:3). Evaporation of the solvent gave amide 10 (1.53 g, 72%, dried under vacuum), mp. 114-115°. IR (KBr): 3005 (Ar-H), 1640

(NC=O) cm⁻¹; ¹H NMR (DCCl₃): δ 1.59 (bs, 2 H), 1.84 (d, 1 H), 1.90 (d, 1 H), 2.16 (s, 1 H), 2.39 (d, 1 H), 2.77 (d, 1 H), 3.17 (m, 2 H), 3.43 (d, 1 H), 3.88 (d, 1 H), 4.97 (d, 1 H), 7.08 (d, 2 H), 7.44 (d, 2 H); ¹³C NMR (DCCl₃): δ 26.4, 26.7, 31.6, 31.7, 32.1, 46.2, 52.0, 114.9, 115.2, 128.7, 128.8, 133.60, 133.64, 161.0, 164.1 (d, *C*-F), 169.1 (NC=O). GC-MS (EI): Calcd for C₁₄H₁₆FNOS: 265. Found: 265. Although **10** appeared stable, it was usually converted to **11h** at once.

Preparation of 11a.- To a stirred and chilled solution of amine **3** (0.6 g, 2.76 mmol) in anhydrous ether (20 mL) was added HClO₄ (60%, 0.69 g, 4.14 mmol) dropwise over 10 min. Stirring for another 10 min produced a precipitate which was collected and washed (dry ether). Recrystallization (ether:H₃CCN, 2:1) afforded **11a** (0.72 g, 83%) as a white solid, mp. 188-189° (dec). IR (KBr): 3310 (N-H), 3035 (Ar-H) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 1.79 (d, 1 H), 1.85 (d, 1 H), 1.95 (bs, 2 H), 3.22 (d, 2 H), 3.40 (d, 2 H), 3.62 (d, 2 H), 3.95 (d, 2 H), 4.25 (s, 2 H), 7.45 (m, 5 H, Ar-H), 8.6 (bs, 1 H); ¹³C NMR (DMSO-*d*₆): δ 28.2, 28.3, 56.0, 60.9, 71.0, 128.9, 129.66, 129.69, 131.2 (Ar-C); MS (HRMS): Calcd for $C_{14}H_{20}CINO_5$: 218.1544. Found: 218.1539

Preparation of 11b.- To a solution of ketone **2** (1.40 g, 6.06 mmol) in methylene chloride (15 mL) was added 1,2-ethanedithiol (0.71 g, 7.57 mmol) followed by boron trifluoride etherate (2.22 mL) in one portion. After stirring overnight, the solution was treated with 5% sodium hydroxide (20 mL). The organic layer was washed (water and brine) and dried (MgSO₄). Concentration of the solution gave a solid which was recrystallized (hexane:EtOAc, 3:1) to give **11b** (1.52 g, 82%), mp. 79.5-80.5°. IR (KBr) 3039 (Ar-H) cm⁻¹; ¹H NMR (DCCl₃) δ 1.89 (bs, 2 H), 2.87 (d, 2 H), 2.95 (d, 2 H), 3.22 (m, 4 H), 3.53 (s, 2 H), 3.98 (d, 2 H), 4.15 (d, 2 H), 7.30 (m, 5 H, Ar-H); ¹³C NMR (DCCl₃) ppm 38.1, 44.0, 56.6, 62.0, 70.5, 71.7, 126.7, 128.1, 128.6, 138.5 (Ar-C). Amine **11b** was converted at once to **11c**. *Anal.* Calcd for C₁₆H₂₁NOS₂: C, 62.54; H, 6.84; N, 4.56. Found: C, 62.35; H, 6.91; N, 4.49

Preparation of 11c.- To a solution of amine **11b** (0.100 g, 0.325 mmol) in anhydrous ether (10 mL) was added HClO₄ (60%, 0.081 g, 0.488 mmol) dropwise over 5 min. The remainder of the procedure was identical to that to obtain **11a**. Recrystallization (H₃COH) of the product gave **11c** (0.120 g, 87%) as a white solid, mp. 196-196.5°. IR (KBr): 3015 (Ar-H), 1084 (Cl-O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 2.17 (s, 2 H), 3.32 (m, 6 H), 3.66 (d, 2 H), 3.97 (d, 2 H), 4.11 (d, 2 H), 4.30 (d, 2 H), 7.50 (m, 5 H, Ar-H), 8.85 (bs, 1 H); ¹³C NMR (DMSO-*d*₆): δ 38.4, 41.4, 55.0, 60.1, 68.7, 70.2, 128.7, 128.8, 129.8, 131.6 (Ar-C).

Anal. Calcd C₁₆H₂₂ClNO₅S₂: C, 47.12; H, 5.39; N, 3.43. Found: C, 46.99; H, 5.38; N, 3.35

Preparation of 11d.- To amide **5** (0.450 g, 1.80 mmol) in DMSO (8 mL) was added imidazole (0.184 g, 2.70 mmol), K_2CO_3 (anhydrous powder, 0.561 g, 4.06 mmol) and 18-C-6 (0.100 g). The mixture was stirred and heated (~110°, 48 h), cooled to RT, and diluted with chilled (ice) water (10 mL). Combined extracts (H₂CCl₂, 4 x 8 mL) of the mixture were washed (water and brine) and dried (MgSO₄). Filtration and concentration of the solution gave a light yellow oil which was chromatographed (silica gel) with hexane:EtOAc:H₃COH (3:3:1) to give the expected intermediate (0.200 g, 38%) as a clear, viscous oil. IR (Film): 3108 (Ar-H), 1628 (NC=O) cm⁻¹; ¹HNMR (DCCl₃): δ 1.60 (bs, 1 H), 1.82 (bs, 1 H), 1.90 (dd, 1 H), 1.97 (dd, 1 H), 2.25 (bs, 2 H), 3.07 (d, 1 H), 3.42 (d, 1 H),

3.88 (m, 2 H), 4.13 (d, 1 H), 4.96 (d, 1 H), 7.18 (s, 1 H), 7.25 (d, 2 H), 7.39 (d, 1 H), 7.41 (d, 2 H), 7.85 (d, 1 H); ¹³C NMR (DCCl₃): δ 28.7, 30.0, 30.7, 48.7, 52.8, 53.4, 55.0, 114.3, 120.0, 121.7, 130.9, 139.5, 166.2 (NC=O). GC-MS (EI): Calcd for C₁₇H₁₉N₃O₂: 297. Found: 297. To a chilled (0°) solution of the above amide (0.160 g, 0.53 mmol) in anhydrous ether:anhydrous THF (1:1, 10 mL) was added HClO₄ (60%, 0.135 g, 0.80 mmol) dropwise (5 min). The resulting solution was stirred vigorously to form a precipitate which was filtered, washed (ether), and recrystallized (H₃COH:H₃CCN, 3.5:1) to give **11d** (0.109 g, 51%), mp. 242-242.5°. IR (KBr): 3150 (N-H), 1625 (NC=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 1.61 (bs, 1 H), 1.80-1.89 (m, 3 H), 3.07 (d, 1 H), 3.44 (d, 1 H), 3.61-3.68 (m, 4 H), 3.91 (d, 1 H), 4.72 (d, 1 H), 7.56 (d, 2 H, imidazole C-*H*, Ar-H), 7.87-7.94 (m, 4 H, imdazole C-*H*, Ar-H), 8.32 (s, 1 H, C-H, imidazole), 9.70 (s, 1 H); ¹³C NMR (DMSO-*d*₆): δ 28.78, 28.87, 30.6, 45.8, 51.4, 71.1, 71.4, 120.8, 121.1, 122.2, 127.9, 134.7, 134.8, 138.5 (Ar-C, imidazole C-H), 167.8 (NC=O). MS (LSIMS): Calcd for C₁₇H₂₀ClN₃O₆: 298 (- ClO₄⁻). Found: 298.

Anal. Calcd for $C_{17}H_{20}ClN_{3}O_{6}H_{2}O$: C, 49.10; H, 5.29; N, 10.10. Found: C, 49.54; H, 4.96; N, 10.00 **Preparation of 11e**.- To a mixture of **4** (0.320 g, 2.51 mmol) in $H_{2}CCl_{2}$ (5 mL) and aqueous NaOH (10%, 2.01 g, 5.03 mmol) was added a solution of 4-nitrobenzenesulfonyl chloride (0.690 g, 3.14 mmol) in $H_{2}CCl_{2}$ (10 mL) dropwise (10 min). After stirring (15 h, RT), water (20 mL) was added, and the aqueous layer was separated and extracted ($H_{2}CCl_{2}$, 3 x 10 mL). Combining the organic layer/extracts gave a solution which was dried (MgSO₄) filtered, and concentrated. Recrystallization (EtOAc:-hexane, 3.5:1) of the solid gave **6** (0.455 g, 58%), mp. 177.5-178.5°. IR (KBr): 3113 (Ar-H) cm⁻¹; ¹H NMR (DCCl₃): δ 1.45 (d, 2 H), 1.73 (bs, 2 H), 2.70 (d, 2 H), 3.58 (d, 2 H), 3.72-3.79 (m, 4 H), 7.94-7.99 (d, 2 H), 8.38-8.43 (d, 2 H); ¹³C NMR (DCCl₃): δ 28.1, 28.7, 49.4, 70.6, 124.6, 128.9, 141.8, 149.9 {Ar-C). MS (LSIMS): calcd for $C_{13}H_{16}N_{2}O_{5}S$: 312. Found: 313 (M⁺ + 1).

Anal. Calcd for C₁₃H₁₆N₂O₅S: C, 50.00; H, 5.12; N, 8.97. Found: C, 50.04; H, 5.16; N, 8.96.

Sulfonamide **6** (0.140 g, 0.448 mmol) in acetic acid:water (1:1) was stirred vigorously until a homgeneous solution formed. To the solution was added TiCl₃ (12%, 4.84 g, 3.14 mmol) in one portion, and the resulting solution was stirred (1.5 h, RT). After cooling (0-5°), the solution was treated with aqueous 20% NaOH until a dark blue color persisted (pH~12). Combined extracts (HCCl₃, 4 x 15 mL) were washed (water and brine), dried (MgSO₄), and concentrated to an oil. Crystallization was induced (EtOAc), followed by chilling (-10°), and gave **11e** (0.100 g, 79%) as a solid, mp. 183-183.5°. IR (KBr): 3380 (N-H), 3040 (Ar-H), 1160 (S=O) cm⁻¹; ¹H NMR (DCCl₃): δ 1.87 (d, 1 H), 1.95 (d, 3 H), 2.18 (s, 1 H), 2.38 (d, 1 H), 2.79 (d, 2 H), 3.18 (m, 2 H), 3.48 (d, 1 H), 3.94 (bs, 2 H), 5.03 (d, 1 H), 7.64 (d, 2 H), 8.28 (d, 2 H)); ¹³C NMR (DCCl₃): δ 26.3, 26.74, 31.6, 31.7, 32.1, 46.2, 52.0, 123.4, 123.8, 127.5, 143.4 (Ar-C). MS (LSIMS): Calcd for C₁₃H₁₈N₂O₃S: 282. Found: 283 (M⁺ + 1).

Anal. Calcd for C₁₃H₁₈N₂O₃S: C, 55.31; H, 6.38; N, 9.92. Found: C, 55.26; H, 6.40; N, 10.00

Preparation of 11f.- A mixture of ketone 7^7 (0.501 g, 2.03 mmol), ethanedithiol (0.286 g, 3.04 mmol), and boron trifluoride etherate (0.5 mL) was stirred at RT overnight and was then treated with 5% sodium hydroxide (20 mL). The aqueous mixture was extracted (H₂CCl₂, 3 x 40 mL), and the combined extracts were dried (Na₂SO₄), filtered, and concentrated to yield a light yellow solid (0.548

g, 83%), mp. 50-51°. IR (KBr): 3040 (Ar-H) cm⁻¹; ¹H NMR (DCCl₃): δ 1.45-2.90 (m, 10 H), 3.10 (s, 4 H), 3.55 (s, 2 H), 7.1-7.5 (m, 5 H, Ar-H). GC-MS (EI): Calcd for C₁₆H₂₁NS₂: 323. Found: 323. The above aminoketone (0.30 g, 0.96 mmol) was immediately placed in a mixture of ether:H₃COH (1:1) at 0° and treated with HClO₄ (60%, 0.241 g, 1.44 mmol) with stirring over 10 min. After stirring for another 10 min, the mixture was allowed to warm to RT. Recrystallization (hot H₃COH using a ratio of approximately 25 mL/0.5 g of solid) of the filtered solid gave **11f** (0.25 g, 63%), mp. 139.5-141°. IR (KBr): 3040 (Ar-H) cm⁻¹; ¹H NMR (DMSO-d₆): δ 1.40-2.95 (m, 10 H), 3.11 (s, 4 H), 3.45 (bs, 2 H), 7.14-7.60 (m, 5 H, Ar-H), 8.95 (bs, 1 H); ¹³C NMR (DMSO-d₆): δ 27.5, 31.5, 44.1, 53.1, 59.8, 61.2, 71.2, 127.2, 128.4, 128.9, 137.6 (Ar-C).

Anal. Calcd for C₁₆H₂₂ClNO₄S₂: C, 49.33; H, 4.87; N, 10.15. Found: C, 49.34; H, 4.82; N, 10.06

Preparation of 11g.- Into a chilled (5°) solution of 12^7 (5.00 g, 20.2 mmol) in ether (150 mL) was bubbled (~4 small bubbles/sec) anhydrous HCl gas over 0.25 h. The mixture was stirred for another 0.25 h and a precipitate formed. Filtration, washing with cold, dry ether, and recrystallization (H₃COH:ether, 1:1) gave a solid **11g** which was dried (80°/0.2 mm, 3.31 g, 61%), mp. 246-247°. IR (KBr): 3040 (Ar-H) cm⁻¹; ¹H NMR (DMSO- d_6): δ 1.84 (m, 2 H), 2.38 (m 2 H), 2.71 (d, 2 H), 3.13 (d, 2 H), 3.36 (bs, 2 H), 3.60 (d, 2 H), 4.29 (d, 2 H), 7.61-7.79 (m, Ar-H), 9.25 (bs, 1 H); ¹³C NMR (DMSO- d_6): δ 25.9, 28.6, 30.9, 56.4, 60.8, 129.2, 129.8, 130.1, 130.4 (Ar-C); MS (HRMS): Calcd for C₁₄H₂₀CINS: 233.1238. Found: 233.1239.

Anal. Calcd for C₁₄H₂₀CINS: C, 62.32; H, 7.47; N, 5.19. Found: C, 62.20; H, 7.38; N, 5.16

Preparation of 11h.- To amide 10 (1.14 g, 4.31 mmol) in dry DMSO (10 mL) was added imidazole (0.44 g, 6.46 mmol) and oil-free KH (0.26 g, 6.46 mmol) along with 18-C-6 (0.100 g). This mixture was stirred at ~105° (24 h) and was then allowed to cool to RT before adding ice water (30 mL). Combined extracts (H₂CCl₂, 4 x 30 mL) of the aqueous layer were washed (chilled water and brine) and dried (Na_2SO_4) . Filtration and concentration of the solution gave a light yellow oil which was chromatographed (neutral alumina) with EtOAc:-hexane (2:3) to yield a light oil which was further chromatographed (silica gel, EtOAc:-methanol, 25:1) to give the intermediate as a light, colorless oil. IR (Film): 3110 (Ar-H), 1620 (NC=O) cm⁻¹; ¹H NMR (DCCl₃): δ 1.64 (bs, 2 H), 1.87 (d, 1 H), 1.91 (d, 1 H), 2.19 (s, 1 H), 2.40 (d, 1 H), 2.78 (d, 1 H), 3.15 (m, 2 H), 3.47 (d, 1 H), 3.90 (d, 1 H), 5.05 (d, 1 H), 7.24 (s, 1 H), 7.41-7.54 (dd, 4 H), 7.67 (s, 1 H), 7.89 (s, 1 H); ¹³C NMR (DCCl₃): δ 27.3, 27.9, 29.8, 41.6, 42.5, 48.3, 55.6, 115.8, 116.2, 118.0, 127.6, 128.9, 131.2, 135.7, 136.9, 137.5 (Ar-C, C-H imidazole), 168.8 (NC=O). GC-MS (EI): Calcd for $C_{17}H_{10}N_3OS$: 313. Found: 313. To this intermediate (0.27 g, 0.86 mmol) in chilled (5°) ether: methanol (1:1, 30 mL) was slowly added $HClO_4$ (60%, 0.22 g, 1.29 mmol) which gave a white solid. The mixture was stirred (10 min) and allowed to warm to RT. Filtration and recrystallization (hot H₃COH, ~10 mL/0.5 g of solid) gave 11h (0.22 g, 61%), mp. 168-170°. IR (KBr): 3200 (N-H), 3005 (Ar-H), 1645 (NC=O) cm⁻¹; ¹H NMR (DMSO- d_{ϵ}): δ 1.76 (d, 1 H), 1.86 (d, 1 H), 2.03 (d, 2 H), 2.34 (d, 1 H), 2.50 (s, 2 H), 2.62 (d, 2 H), 3.09 (m, 3 H), 3.50 (d, 1 H), 3.67 (d, 1 H), 7.62 (d, 2 H), 7.80 (d, 2 H), 7.95 (s, 1 H), 8.32 (s, 1 H), 9.71 (bs, 1 H); ¹³C NMR (DMSO- d_6): δ 27.8, 29.7, 41.6, 55.4, 120.6, 121.3, 122.0, 1128.7, 135.3, 137.5 (Ar-C, C-H imidazole), 171.5 (NC=O). Anal. Calcd for $C_{17}H_{20}ClN_3O_5S$: C, 49.33; H, 4.87; N, 10.15. Found: 49.34; H, 4.82; N, 10.06

Acknowledgments.- We gratefully thank the College of Arts and Sciences of the Oklahoma State University for partial support of this work. We (KDB) also acknowledge partial support by Grant KS2-445 of the U.S. Civilian R&D Foundation for the Independent States of the Former Soviet Union.

REFERENCES

- a) J. M. Elliott, H. G. Selnick, D. A. Claremon, J. J. Baldwin, S. A. Buhrow, J. W. Butcher, C. N. Habecker, S. W. King, J. J. Lynch, Jr., B. T. Phillips, G. S. Ponticello, E. M. Radzilowski, D. C. Remy, R. B. Stein, J. I. White and M. B. Young, J. Med. Chem., 35, 3973 (1992); b) J. W. Mason, The New Engl. J. Med., 329, 452 (1993); c) J. L. Anderson, J. Cardiovascul. Electro-physiol., 6, 880 (1995).
- a) M. Rashack, Arzneim.-Forschung, 24, 753 (1974); b) T. Izaba, S. V. Otton and W. Kalow, Clin. Pharmacol. Ther., 27, 547 (1980); c) M. Eichelbaun, Trends in Pharmacol. Sci., 2, 31, (1981).
- a) G. S. Smith, M. D. Thompson, K. D. Berlin, E. M. Holt, B. J. Scherlag, E. Patterson and R. Lazzara, *Eur. J. Med. Chem.*, 25, 1 (1990); b) T. Fazkas, L. Carlsson, B. J. Scherlag, P. Mabo, H. Poty, M. Palmer, E. Patterson, K. D. Berlin, G. L. Garrison, and R. Lazzara, *J. Cardiovasc. Pharmacol.*, 28, 182 (1996).
- 4. The area was reviewed by N. S. Zefirov and V. A. Palyulin, Top. Stereochem., 20, 171 (1991).
- G. Buschmann, D. Zeigler, G. Varchman, U. G. Kuhl, G. N. Beach and M. J. A. Walker, J. Molec. Cell Cardiol., 21, (Suppl II) S, 17 (1989).
- G. N. Beach, S. Abraham, N. R. MacLeod, N. A. Yoshida and M. J. A. Walker, Br. J. Pharmacol., 102, 13 (1991).
- B. R. Bailey, Jr., K. D. Berlin, E. M. Holt, B. J. Scherlag, R. Lazzara, J. Brachmann, D. van der Helm, D. R. Powell, N. S. Pantaleo and P. C. Ruenitz, J. Med. Chem. 27, 758 (1984).
- T. K. Morgan, Jr., R. Lis, W. C. Lumma, Jr., R. A. Wohl, K. Nickisch, G. B. Phillips, J. M. Lind, J. W. Lampe, S. V. DiMeo, H. J. Reiser, T. M. Argentieri, M. E. Sullivan and E. Cantor, *Ibid.*, 33, 1087 (1990).
- W. C. Lumma, Jr., R. A. Wohl, D. D. Davey, T. M. Argentieri, R. J. DeVita, R. P. Gomez, V. K. Jain, A. J. Marisca, T. K. Morgan, Jr., H. J. Reiser, M. E. Sullivan, J. Wiggins and S. S, Wong, *Ibid.*, 30, 755 (1987).
- 10. D. L. D. Keefe, R. E. Kates and D. C. Harrison, Drugs, 22, 363 (1981).
- 11. J. Jurczak, M. Tkacz and U. Majchrak-Kuczynska, Synthesis, 920 (1983).

(Received July 27, 1999; in final for August 31, 1999)